OrthoPediatrics Announces FDA 510(k) Clearance of PNP | Femur Retrograde Nail System and Completes First Implantations
OrthoPediatrics received FDA 510(k) clearance for the PNP | Femur Retrograde Nail System and has already completed the first implantations. The system was designed specifically for pediatric anatomy, offering anatomic nails for trauma and straight nails for deformity, and leverages existing PNP instrumentation. Availability begins via limited market release through the rest of 2026, with broader commercialization planned for 2027.
Key figures
- Drug Name
- PNP | Femur Retrograde Nail System (PNP Retrograde)
- Systems marketed
- 95
- Platform patients
- nearly 15,000
- Nail diameter range mm
- 7 to 11
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.